MDNAF News and Press, Mandatum Pankki Oyj From 09/12/19

TORONTO and HOUSTON , Sept. 12, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present updated clinical results from the Phase 2b clinical trial...

Medicenna Therapeutics ( OTCQB:MDNAF ): Q1 GAAP EPS of -$0.05 misses by $0.02 . More news on: Medicenna Therapeutics Corp., Earnings news and commentary, Consumer stocks news, , Read more ...

Medicenna Reports First Quarter Fiscal 2020 Financial Results Canada NewsWire TORONTO and HOUSTON, Aug. 9, 2019 TORONTO and HOUSTON , Aug. 9, 2019 /CNW/ - Medicenna Therapeutics Corp. (" Medicenna " or the " Company ") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-...

Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform Canada NewsWire TORONTO and HOUSTON, July 31, 2019 MDNA19 demonstrates robust efficacy and safety with or without checkpoint inhibitors in preclinical models; Clinical s...

TORONTO and HOUSTON , July 9, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$1,915,264 (approximately, CD$2.5M) from the Cancer Prevention and ...

Scientists at the NIH and FDA Demonstrate Impressive Synergy of MDNA55 with Interferons  TORONTO and HOUSTON, June 26, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is...

Medicenna Therapeutics ( OTCQB:MDNAF ): FY GAAP EPS of -C$0.18. More news on: Medicenna Therapeutics Corp., Earnings news and commentary, Consumer stocks news, , Read more ...

Medicenna Announces March 31, 2019 Year-End Results Canada NewsWire TORONTO and HOUSTON, TX, June 25, 2019 TORONTO and HOUSTON, TX , June 25, 2019 /CNW/ - Medicenna Therapeutics Corp. (" Medicenna " or the " Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunot...

Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109 Canada NewsWire TORONTO and HOUSTON, June 20, 2019 - Long Acting MDNA109 provides durable tumor control and strong memory response without further treatment when combined with checkpoint inhi...

TORONTO and HOUSTON , June 19, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that Dr. Fahar Merchant, Chairman, President and CEO will present an overv...